ArticleResearch in pharmaceutical sciences2024
Antioxidant and anti-inflammatory activity by modulating IL-6 as a potential mechanism in the nephroprotective and hepatoprotective properties of
Article in Research in pharmaceutical sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Nonclinical Safety Evaluation of Renogrit: In Vitro Nonmutagenicity (OECD 471) and 28-Day Repeated Oral Dose Toxicity (OECD 407) in Sprague Dawley Rats.Journal of toxicology · 2026Article
- Bioactive Compounds, Antibacterial, Antioxidant, Anticancer, and Antidiabetic Potential of the Seed and Leaves ofLife (Basel, Switzerland) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and purpose: Carboplatin, a second-generation platinum-containing compound is associated with renal tubular injury and hepatic damage in cancer patients. Experimental approach: Findings/Results: TT at 1.5 g/kg on day 14 significantly reduced creatinine and aspartate transaminase levels compared to the carboplatin group. The increase in malondialdehyde levels and decrease in glutathione levels was significantly reversed in the groups treated with TT 1.25 and 1.5 g/kg. Interleukin 6 showed a significant decrease in treatment groups when compared to the carboplatin group. Carboplatin distorted hepatic architecture and caused diffused inflammatory cell infiltration in the peritubular interstitial spaces in the kidney. The histopathological evaluation confirmed that TT extract ameliorated hepatic and kidney damage by restoring to normal architecture. Conclusion and implications: Aqueous extract of TT demonstrated a therapeutic effect against nephrotoxicity and hepatotoxicity caused by carboplatin. The observed benefits can be attributed to its anti-inflammatory action and antioxidant properties.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.